1. Home
  2. SLXN vs SEED Comparison

SLXN vs SEED Comparison

Compare SLXN & SEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • SEED
  • Stock Information
  • Founded
  • SLXN 2008
  • SEED 1997
  • Country
  • SLXN Israel
  • SEED China
  • Employees
  • SLXN N/A
  • SEED N/A
  • Industry
  • SLXN
  • SEED Farming/Seeds/Milling
  • Sector
  • SLXN
  • SEED Consumer Staples
  • Exchange
  • SLXN NYSE
  • SEED Nasdaq
  • Market Cap
  • SLXN 7.3M
  • SEED 7.6M
  • IPO Year
  • SLXN N/A
  • SEED N/A
  • Fundamental
  • Price
  • SLXN $0.83
  • SEED $0.86
  • Analyst Decision
  • SLXN Strong Buy
  • SEED
  • Analyst Count
  • SLXN 1
  • SEED 0
  • Target Price
  • SLXN $5.00
  • SEED N/A
  • AVG Volume (30 Days)
  • SLXN 784.5K
  • SEED 111.9K
  • Earning Date
  • SLXN 08-21-2025
  • SEED 06-26-2025
  • Dividend Yield
  • SLXN N/A
  • SEED N/A
  • EPS Growth
  • SLXN N/A
  • SEED N/A
  • EPS
  • SLXN N/A
  • SEED N/A
  • Revenue
  • SLXN N/A
  • SEED $12,910,081.00
  • Revenue This Year
  • SLXN N/A
  • SEED N/A
  • Revenue Next Year
  • SLXN N/A
  • SEED N/A
  • P/E Ratio
  • SLXN N/A
  • SEED N/A
  • Revenue Growth
  • SLXN N/A
  • SEED N/A
  • 52 Week Low
  • SLXN $0.58
  • SEED $0.74
  • 52 Week High
  • SLXN $41.85
  • SEED $3.82
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • SEED 31.72
  • Support Level
  • SLXN N/A
  • SEED $0.82
  • Resistance Level
  • SLXN N/A
  • SEED $1.04
  • Average True Range (ATR)
  • SLXN 0.00
  • SEED 0.08
  • MACD
  • SLXN 0.00
  • SEED -0.01
  • Stochastic Oscillator
  • SLXN 0.00
  • SEED 40.63

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

Share on Social Networks: